MY122707A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number: MY122707A
Authority: MY; Malaysia
Prior art keywords: pharmaceutical compositions; dihydroxyhept; multivalent; methylsulfonyl; pyrimidin
Prior art date: 2000-01-26

Application number

MYPI20003567A

Other languages

English (en)

Inventor

Joseph Richard Creekmore

Norman Alfred Wiggins

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-26

Filing date

2000-08-04

Publication date

2006-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY122707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-04-29 Publication of MY122707A publication Critical patent/MY122707A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MYPI20003567A 2000-01-26 2000-08-04 Pharmaceutical compositions MY122707A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0001621.2A GB0001621D0 (en)	2000-01-26	2000-01-26	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
MY122707A true MY122707A (en)	2006-04-29

Family

ID=9884259

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MYPI20003567A MY122707A (en)	2000-01-26	2000-08-04	Pharmaceutical compositions
MYPI20003568 MY123650A (en)	2000-01-26	2000-08-04	Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MYPI20003568 MY123650A (en)	2000-01-26	2000-08-04	Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Country Status (48)

Country	Link
US (2)	US6548513B1 (it)
EP (6)	EP2266540A1 (it)
JP (3)	JP4800467B2 (it)
KR (3)	KR100698333B1 (it)
CN (3)	CN100528161C (it)
AP (2)	AP1449A (it)
AR (3)	AR025055A1 (it)
AT (3)	AT412062B (it)
AU (5)	AU2000264559A1 (it)
BE (2)	BE1013414A5 (it)
BG (4)	BG65234B1 (it)
BR (2)	BR0003365A (it)
CA (3)	CA2315141C (it)
CH (2)	CH700184B1 (it)
CL (1)	CL2007001807A1 (it)
CR (3)	CR6568A (it)
CZ (3)	CZ299105B6 (it)
DE (3)	DE10038108A1 (it)
DK (3)	DK1223918T3 (it)
EE (3)	EE05586B1 (it)
ES (2)	ES2171123B1 (it)
FI (3)	FI121365B (it)
FR (2)	FR2795324B1 (it)
GB (3)	GB0001621D0 (it)
HK (4)	HK1047052A1 (it)
HR (3)	HRP20080525A2 (it)
HU (2)	HU222578B1 (it)
IL (4)	IL147870A (it)
IS (3)	IS1940B (it)
IT (2)	ITTO20000780A1 (it)
ME (4)	ME00202B (it)
MY (2)	MY122707A (it)
NL (2)	NL1015858C2 (it)
NO (4)	NO312434B1 (it)
NZ (2)	NZ531474A (it)
PL (2)	PL341855A1 (it)
PT (3)	PT102504A (it)
RS (1)	RS50201B (it)
RU (2)	RU2206324C1 (it)
SE (2)	SE523471C2 (it)
SI (1)	SI1223918T1 (it)
SK (2)	SK11792000A3 (it)
TR (3)	TR200200270T2 (it)
TW (2)	TW553749B (it)
UA (2)	UA51853C2 (it)
WO (2)	WO2001054669A1 (it)
YU (1)	YU52902A (it)
ZA (2)	ZA200003997B (it)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
USRE44578E1 (en)	2000-04-10	2013-11-05	Teva Pharmaceutical Industries, Ltd.	Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL152179A (en) †	2000-04-10	2009-06-15	Teva Pharma	Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) *	2000-08-08	2004-12-24	Smithkline Beecham P	A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) *	2000-11-22	2001-01-10	Astrazeneca Ab	Therapy
EP1911462A3 (en) *	2001-01-26	2011-11-30	Schering Corporation	Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) *	2001-01-30	2011-02-08	Smithkline Beecham Limited	Pharmaceutical formulation
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
US20050175687A1 (en) *	2001-01-30	2005-08-11	Mcallister Stephen M.	Pharmaceutical formulations
US7842308B2 (en) *	2001-01-30	2010-11-30	Smithkline Beecham Limited	Pharmaceutical formulation
KR20040026705A (ko) *	2001-08-16	2004-03-31	테바 파마슈티컬 인더스트리즈 리미티드	스타틴의 칼슘 염 형태의 제조 방법
US20060039967A1 (en) *	2002-08-12	2006-02-23	Motohiro Ohta	Amino acid-containing chewable
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
US20080293750A1 (en) *	2002-10-17	2008-11-27	Anna Helgadottir	Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) *	2002-10-17	2006-01-26	Decode Genetics, Inc.	Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl)	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
TW200526274A (en) *	2003-07-21	2005-08-16	Smithkline Beecham Plc	Pharmaceutical formulations
US7396927B2 (en) *	2003-08-28	2008-07-08	Teva Pharmaceutical Industries Ltd.	Process for preparation of rosuvastatin calcium
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
PT2821067T (pt) *	2003-09-12	2017-12-01	Amgen Inc	Formulação de cinacalcet de dissolução rápida
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
CA2546701C (en) *	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de) *	2003-12-02	2011-06-09	Teva Pharma	Referenzstandard zur charakterisierung von rosuvastatin
US8158362B2 (en) *	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) *	2004-01-30	2010-08-26	Decode Genetics Ehf.	Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
TW201240679A (en) *	2004-03-12	2012-10-16	Capsugel Belgium Nv	Pharmaceutical formulations
AU2005240137B2 (en) *	2004-05-04	2010-04-15	Innophos, Inc.	Directly compressible tricalcium phosphate
GB0411378D0 (en) *	2004-05-21	2004-06-23	Astrazeneca Ab	Pharmaceutical compositions
CN1323665C (zh) *	2004-06-16	2007-07-04	鲁南制药集团股份有限公司	治疗高血脂症的组合物
WO2006017357A1 (en) *	2004-07-13	2006-02-16	Teva Pharmaceutical Industries Ltd.	A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
AU2005271407A1 (en) *	2004-08-06	2006-02-16	Transform Pharmaceuticals, Inc.	Novel fenofibrate formulations and related methods of treatment
WO2006091770A2 (en)	2005-02-22	2006-08-31	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) *	2005-02-22	2007-02-15	Valerie Niddam-Hildesheim	Preparation of rosuvastatin
US20070167625A1 (en) *	2005-02-22	2007-07-19	Anna Balanov	Preparation of rosuvastatin
RU2303980C2 (ru) *	2005-06-03	2007-08-10	ОАО "Щелковский витаминный завод"	Лекарственная форма с антиагрегационным действием и способ ее изготовления
EP1922065A4 (en) *	2005-08-04	2009-11-11	Transform Pharmaceuticals Inc	NEW FORMULATIONS WITH FENOFIBRATE AND A STATIN AND RELEVANT TREATMENT PROCESS
KR20070062996A (ko) *	2005-08-16	2007-06-18	테바 파마슈티컬 인더스트리즈 리미티드	결정성 로수바스타틴 중간체
PL1928409T3 (pl)	2005-09-12	2013-02-28	Actelion Pharmaceuticals Ltd	Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid
ES2375643T3 (es) *	2005-10-31	2012-03-02	Kowa Company, Ltd.	Preparación farmacéutica que presenta excelente fotoestabilidad.
AU2006329006B2 (en) *	2005-12-20	2013-02-28	Lek Pharmaceuticals D.D.	Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) *	2006-04-13	2011-12-28	Egyt Gyogyszervegyeszeti Gyar	Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) *	2006-05-03	2016-11-28	Msn Laboratories Private Ltd	A novel process for statins and their pharmaceutically acceptable salts
HU227610B1 (en) *	2006-09-18	2011-09-28	Richter Gedeon Nyrt	Pharmaceutical compositions containing rosuvastatin potassium
ES2567171T3 (es) *	2006-10-09	2016-04-20	Msn Laboratories Private Limited	Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
US20080249141A1 (en) *	2007-04-06	2008-10-09	Palepu Nageswara R	Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124120A1 (en) *	2007-04-09	2008-10-16	Scidose, Llc	Combinations of statins and anti-obesity agent
WO2008124122A1 (en) *	2007-04-09	2008-10-16	Scidose, Llc	Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) *	2007-07-05	2013-06-05	江苏正大天晴药业股份有限公司	一种稳定的药物组合物
WO2009095934A1 (en) *	2008-01-30	2009-08-06	Lupin Limited	Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) *	2008-03-11	2009-09-17	Belupo-Lijekovi I Kozmetika D.D.	Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (zh)	2008-05-27	2009-12-03	常州制药厂有限公司	瑞舒伐他汀钙盐的制备方法及其中间体
AU2009256572A1 (en) *	2008-06-13	2009-12-17	Capsugel Belgium Nv	Hydroxypropyl cellulose capsule shell
BRPI0822782A2 (pt) *	2008-06-27	2015-09-29	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	composição farmacêutica que compreende rosuvastatina
PT2309992T (pt) *	2008-06-27	2018-01-22	Krka Tovarna Zdravil D D Novo Mesto	Composição farmacêutica compreendendo uma estatina
EP2138165A1 (en)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising a statin
PL386051A1 (pl) *	2008-09-09	2010-03-15	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) *	2008-09-30	2018-11-29	EGIS Gyógyszergyár NyR	Stabil kombinációs gyógyszerkészítmény
MX344885B (es) *	2008-11-10	2017-01-10	Psicofarma S A De C V	Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en)	2009-01-19	2010-08-12	Msn Laboratories Limited	Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr)	2009-03-17	2010-01-21	Sanovel İlaç San.Veti̇c.A.Ş.	Stabil rosuvastatin kompozisyonları
US8470805B2 (en) *	2009-04-30	2013-06-25	Kaohsiung Medical University	Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr)	2009-06-03	2010-12-21	Bi̇lgi̇ç Mahmut	Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
AU2010281913A1 (en)	2009-08-13	2012-04-05	Synthon B.V.	Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en)	2010-01-18	2015-03-24	Msn Laboratories Private Limited	Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) *	2010-02-09	2011-06-08	鲁南贝特制药有限公司	一种含瑞舒伐他汀钙的片剂及其制备工艺
EP2566465A2 (en)	2010-05-04	2013-03-13	Mahmut Bilgic	Stable rosuvastatin formulations
TR201009397A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Rosuvastatin içeren farmasötik bileşimler.
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh)	2010-11-02	2014-12-01	Univ Kaohsiung Medical	Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2698159A4 (en) *	2011-04-12	2014-11-05	Sawai Seiyaku Kk	PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
CA2835364C (en)	2011-05-20	2018-10-02	Astrazeneca Uk Limited	Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) *	2011-05-27	2014-02-27	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтическая композиция для лечения нарушений липидного обмена
WO2013172297A1 (ja) *	2012-05-14	2013-11-21	塩野義製薬株式会社	６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
AR091706A1 (es) *	2012-07-11	2015-02-25	Teva Pharma	Formulaciones de laquinimod sin agentes alcalinizantes
MX374223B (es) *	2013-03-12	2025-03-05	Lg Chemical Ltd	Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
RO129060B1 (ro)	2013-04-25	2014-11-28	Antibiotice S.A.	Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) *	2013-07-09	2015-04-10	Общество с ограниченной ответственностью "Трейдсервис"	Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko)	2013-07-25	2016-02-23	씨제이헬스케어 주식회사	서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR112017009521A2 (pt) *	2014-11-11	2017-12-19	Shionogi & Co	comprimido de múltiplas camadas que contém um fármaco instável à luz
JP2016169198A (ja) *	2015-03-13	2016-09-23	大原薬品工業株式会社	ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) *	2015-04-24	2017-03-15	大原薬品工業株式会社	ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CN118975972A (zh)	2015-10-23	2024-11-19	林德拉治疗公司	用于治疗剂缓释的胃驻留系统及其使用方法
JP7030052B2 (ja)	2015-12-08	2022-03-04	リンドラセラピューティクス，インコーポレイティド	胃滞留システムのための幾何学的構成
EP3243506A1 (en)	2016-05-09	2017-11-15	Adamed sp. z o.o.	Pharmaceutical composition
US12109305B2 (en)	2016-05-27	2024-10-08	Lyndra Therapeutics, Inc.	Materials architecture for gastric residence systems
EP3518902A4 (en)	2016-09-30	2020-07-08	Lyndra, Inc.	GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
CN107913257A (zh) *	2016-10-10	2018-04-17	北京阜康仁生物制药科技有限公司	一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en)	2016-12-20	2020-03-24	Astrazeneca Uk Ltd.	Systems and methods for dispensing a statin medication over the counter
WO2018227147A1 (en)	2017-06-09	2018-12-13	Lyndra, Inc.	Gastric residence systems with release rate-modulating films
JP2018027987A (ja) *	2017-11-24	2018-02-22	共和薬品工業株式会社	医薬組成物
CN112274487A (zh) *	2019-07-25	2021-01-29	北京福元医药股份有限公司	一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) *	2019-10-25	2023-03-28	乐普制药科技有限公司	一种含布立西坦的组合物
US20220008519A1 (en)	2020-07-09	2022-01-13	Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS)	Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en)	2022-09-28	2024-04-03	Novumgen Ltd	A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2262229A (en) *	1939-06-24	1941-11-11	Interchem Corp	Pigment and method of preparation
GB653026A (en)	1947-07-02	1951-05-09	Merck & Co Inc	Vitamin preparations
US4743450A (en)	1987-02-24	1988-05-10	Warner-Lambert Company	Stabilized compositions
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) *	1987-12-10	1990-05-29	Warner-Lambert Company	5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no)	1988-02-25	1989-08-28	Bayer Ag	Substituerte pyrimidiner.
US5030447A (en)	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
JPH03501613A (ja) *	1988-10-06	1991-04-11	サンド・アクチエンゲゼルシヤフト	ピリミジニル置換ヒドロキシ酸、ラクトン及びエステル並びにそれらを含む製薬学的組成物
US5004651A (en)	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms
US5130298A (en)	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
EP0475482B1 (en)	1990-09-13	1994-10-05	Akzo Nobel N.V.	Stabilized solid chemical compositions
RU2086544C1 (ru) *	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
RU2098411C1 (ru) *	1991-08-02	1997-12-10	Иституто Лусо Фармако д Италия С.п.А.	Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU217629B (hu) *	1991-12-12	2000-03-28	Novartis Ag.	Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en)	1992-05-08	1995-12-26	The Green Cross Corporation	Quinoline compounds
DE69324504T2 (de) *	1993-01-19	1999-08-26	Warner-Lambert Co.	Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
NZ324446A (en) *	1995-12-22	1999-08-30	Kowa Co	Pharmaceutical composition containing (e)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropyl-quinolin -3'-yl]-6-heptenoic acid where the aqueous solution or dispersion of the composition has a ph of 7 to less than 8
ATE220543T1 (de) *	1996-04-23	2002-08-15	Janssen Pharmaceutica Nv	Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
WO1999062560A1 (en)	1998-06-05	1999-12-09	Warner-Lambert Company	Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl)	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
GB9900339D0 (en) *	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
US6150410A (en)	1999-02-04	2000-11-21	Abbott Laboratories	pH independent extended release pharmaceutical formulation
GB0000710D0 (en) *	1999-02-06	2000-03-08	Zeneca Ltd	Drug combination
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
AR022462A1 (es)	1999-02-06	2002-09-04	Astrazeneca Uk Ltd	Uso de un agente que disminuye el colesterol
GB0001621D0 (en) *	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
AU3653301A (en)	2000-01-28	2001-08-07	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

2000
- 2000-01-26 GB GBGB0001621.2A patent/GB0001621D0/en not_active Ceased
- 2000-04-08 UA UA2002021419A patent/UA51853C2/uk unknown
- 2000-08-02 NL NL1015858A patent/NL1015858C2/nl not_active IP Right Cessation
- 2000-08-02 NL NL1015859A patent/NL1015859C2/nl not_active IP Right Cessation
- 2000-08-04 CZ CZ20070222A patent/CZ299105B6/cs not_active IP Right Cessation
- 2000-08-04 IL IL14787000A patent/IL147870A/xx active Protection Beyond IP Right Term
- 2000-08-04 CZ CZ20002883A patent/CZ290167B6/cs not_active IP Right Cessation
- 2000-08-04 CN CNB001224859A patent/CN100528161C/zh not_active Expired - Lifetime
- 2000-08-04 HR HR20080525A patent/HRP20080525A2/xx not_active Application Discontinuation
- 2000-08-04 DE DE10038108A patent/DE10038108A1/de not_active Ceased
- 2000-08-04 WO PCT/GB2000/003017 patent/WO2001054669A1/en not_active Ceased
- 2000-08-04 DK DK00953283T patent/DK1223918T3/da active
- 2000-08-04 KR KR1020000045228A patent/KR100698333B1/ko not_active Ceased
- 2000-08-04 FR FR0010334A patent/FR2795324B1/fr not_active Expired - Lifetime
- 2000-08-04 HK HK02108790.3A patent/HK1047052A1/zh unknown
- 2000-08-04 TR TR2002/00270T patent/TR200200270T2/xx unknown
- 2000-08-04 CN CNB001224840A patent/CN1149997C/zh not_active Expired - Lifetime
- 2000-08-04 ME MEP-2008-337A patent/ME00202B/me unknown
- 2000-08-04 ES ES200001999A patent/ES2171123B1/es not_active Expired - Fee Related
- 2000-08-04 TR TR2002/01888T patent/TR200201888T2/xx unknown
- 2000-08-04 ME MEP-337/08A patent/MEP33708A/xx unknown
- 2000-08-04 TW TW089115660A patent/TW553749B/zh not_active IP Right Cessation
- 2000-08-04 US US09/633,114 patent/US6548513B1/en not_active Expired - Fee Related
- 2000-08-04 DK DK200001170A patent/DK200001170A/da not_active Application Discontinuation
- 2000-08-04 AU AU2000264559A patent/AU2000264559A1/en not_active Abandoned
- 2000-08-04 GB GB0019029A patent/GB2358583B/en not_active Expired - Lifetime
- 2000-08-04 HU HU0003110A patent/HU222578B1/hu active IP Right Grant
- 2000-08-04 NZ NZ531474A patent/NZ531474A/en not_active IP Right Cessation
- 2000-08-04 SK SK1179-2000A patent/SK11792000A3/sk not_active Application Discontinuation
- 2000-08-04 EE EEP200900047A patent/EE05586B1/xx unknown
- 2000-08-04 KR KR10-2000-0045229A patent/KR100388713B1/ko not_active Expired - Lifetime
- 2000-08-04 SE SE0002826A patent/SE523471C2/sv not_active IP Right Cessation
- 2000-08-04 JP JP2000237576A patent/JP4800467B2/ja not_active Expired - Lifetime
- 2000-08-04 HK HK03101240.3A patent/HK1048950A1/zh unknown
- 2000-08-04 TW TW089115659A patent/TWI228050B/zh not_active IP Right Cessation
- 2000-08-04 FI FI20001750A patent/FI121365B/fi not_active IP Right Cessation
- 2000-08-04 UA UA2002086973A patent/UA77156C2/xx unknown
- 2000-08-04 PL PL00341855A patent/PL341855A1/xx not_active IP Right Cessation
- 2000-08-04 CH CH01542/00A patent/CH700184B1/de not_active IP Right Cessation
- 2000-08-04 FI FI20001749A patent/FI111806B/fi not_active IP Right Cessation
- 2000-08-04 AP APAP/P/2002/002409A patent/AP1449A/en active
- 2000-08-04 TR TR2007/01171T patent/TR200701171T2/xx unknown
- 2000-08-04 FR FR0010333A patent/FR2804025B1/fr not_active Expired - Lifetime
- 2000-08-04 AU AU51841/00A patent/AU738074B2/en not_active Expired
- 2000-08-04 AT AT0136000A patent/AT412062B/de not_active IP Right Cessation
- 2000-08-04 BR BR0003365-0A patent/BR0003365A/pt not_active Application Discontinuation
- 2000-08-04 AR ARP000104058A patent/AR025055A1/es unknown
- 2000-08-04 AP APAP/P/2002/002591A patent/AP1879A/en active
- 2000-08-04 PT PT102504A patent/PT102504A/pt active IP Right Grant
- 2000-08-04 ZA ZA200003997A patent/ZA200003997B/xx unknown
- 2000-08-04 BE BE2000/0492A patent/BE1013414A5/fr not_active IP Right Cessation
- 2000-08-04 CA CA002315141A patent/CA2315141C/en not_active Expired - Fee Related
- 2000-08-04 CA CA002313783A patent/CA2313783C/en not_active Expired - Fee Related
- 2000-08-04 AR ARP000104057A patent/AR023624A1/es unknown
- 2000-08-04 ES ES200001998A patent/ES2155043B1/es not_active Expired - Fee Related
- 2000-08-04 EP EP10180659A patent/EP2266540A1/en not_active Withdrawn
- 2000-08-04 EE EEP200200411A patent/EE05221B1/xx unknown
- 2000-08-04 NO NO20003967A patent/NO312434B1/no not_active IP Right Cessation
- 2000-08-04 BR BR0003364-2A patent/BR0003364A/pt active IP Right Grant
- 2000-08-04 MY MYPI20003567A patent/MY122707A/en unknown
- 2000-08-04 SE SE0002827A patent/SE523481C2/sv not_active IP Right Cessation
- 2000-08-04 CN CNA200710088942XA patent/CN101028268A/zh active Pending
- 2000-08-04 YU YU52902A patent/YU52902A/sh unknown
- 2000-08-04 PT PT00953283T patent/PT1223918E/pt unknown
- 2000-08-04 IT IT2000TO000780A patent/ITTO20000780A1/it unknown
- 2000-08-04 RU RU2002103603/14A patent/RU2206324C1/ru active
- 2000-08-04 DE DE60001371T patent/DE60001371T2/de not_active Expired - Lifetime
- 2000-08-04 GB GB0019028A patent/GB2358582B/en not_active Expired - Lifetime
- 2000-08-04 HR HR20020632A patent/HRP20020632B1/xx not_active IP Right Cessation
- 2000-08-04 AT AT0136100A patent/AT412063B/de not_active IP Right Cessation
- 2000-08-04 PT PT102503A patent/PT102503B/pt active IP Right Grant
- 2000-08-04 CH CH01541/00A patent/CH691347A5/de not_active IP Right Cessation
- 2000-08-04 JP JP2000237575A patent/JP3267960B2/ja not_active Expired - Lifetime
- 2000-08-04 IL IL15051300A patent/IL150513A0/xx unknown
- 2000-08-04 EP EP00953283A patent/EP1223918B1/en not_active Expired - Lifetime
- 2000-08-04 EP EP00951701A patent/EP1251831A1/en not_active Withdrawn
- 2000-08-04 NZ NZ519774A patent/NZ519774A/en not_active IP Right Cessation
- 2000-08-04 SK SK1178-2000A patent/SK283872B6/sk unknown
- 2000-08-04 CZ CZ20002884A patent/CZ298411B6/cs not_active IP Right Cessation
- 2000-08-04 RU RU2002122752/15A patent/RU2264210C2/ru active
- 2000-08-04 EP EP09171015A patent/EP2133070A1/en not_active Withdrawn
- 2000-08-04 AU AU65800/00A patent/AU6580000A/en not_active Abandoned
- 2000-08-04 ME MEP-338/08A patent/MEP33808A/xx unknown
- 2000-08-04 ZA ZA200003998A patent/ZA200003998B/xx unknown
- 2000-08-04 WO PCT/GB2000/003014 patent/WO2001054668A1/en not_active Ceased
- 2000-08-04 EP EP14170807.3A patent/EP2774609A1/en not_active Withdrawn
- 2000-08-04 AU AU51842/00A patent/AU781269C/en not_active Revoked
- 2000-08-04 PL PL341853A patent/PL196808B1/pl unknown
- 2000-08-04 EE EEP200200052A patent/EE04990B1/xx unknown
- 2000-08-04 NO NO20003968A patent/NO327675B1/no not_active IP Right Cessation
- 2000-08-04 DE DE10038110A patent/DE10038110B4/de not_active Expired - Lifetime
- 2000-08-04 MY MYPI20003568 patent/MY123650A/en unknown
- 2000-08-04 HU HU0003111A patent/HUP0003111A3/hu unknown
- 2000-08-04 EP EP08165575A patent/EP2018853A1/en not_active Withdrawn
- 2000-08-04 RS YU5202A patent/RS50201B/sr unknown
- 2000-08-04 ME MEP-2008-338A patent/ME00191B/me unknown
- 2000-08-04 SI SI200030065T patent/SI1223918T1/xx unknown
- 2000-08-04 AT AT00953283T patent/ATE232088T1/de active
- 2000-08-04 IT IT2000TO000779A patent/ITTO20000779A1/it unknown
- 2000-08-04 DK DK200001171A patent/DK178242B1/da not_active IP Right Cessation
- 2000-08-04 BE BE2000/0491A patent/BE1013413A3/fr not_active IP Right Cessation
- 2000-08-04 HR HR20020097A patent/HRP20020097B1/xx not_active IP Right Cessation
- 2000-08-04 CA CA2639407A patent/CA2639407C/en not_active Expired - Fee Related
- 2000-08-04 US US09/633,064 patent/US6316460B1/en not_active Expired - Lifetime
2002
- 2002-01-29 IS IS6254A patent/IS1940B/is unknown
- 2002-01-30 CR CR6568A patent/CR6568A/es unknown
- 2002-02-06 BG BG106393A patent/BG65234B1/bg unknown
- 2002-04-17 HK HK02102911.0A patent/HK1040936B/zh not_active IP Right Cessation
- 2002-06-26 CR CR6687A patent/CR6687A/es not_active Application Discontinuation
- 2002-07-01 IL IL150513A patent/IL150513A/en unknown
- 2002-07-16 BG BG106926A patent/BG66168B1/bg unknown
- 2002-07-16 BG BG110353A patent/BG110353A/en unknown
- 2002-07-23 IS IS6480A patent/IS6480A/is unknown
2003
- 2003-04-11 KR KR1020030022854A patent/KR20030036492A/ko not_active Ceased
2005
- 2005-06-02 AU AU2005202392A patent/AU2005202392C1/en not_active Expired
2007
- 2007-03-07 IS IS8620A patent/IS2805B/is unknown
- 2007-03-09 NO NO20071303A patent/NO327554B1/no not_active IP Right Cessation
- 2007-03-12 JP JP2007062353A patent/JP4800988B2/ja not_active Expired - Lifetime
- 2007-03-30 AR ARP070101365A patent/AR060248A2/es unknown
- 2007-06-20 CL CL2007001807A patent/CL2007001807A1/es unknown
- 2007-11-15 IL IL187416A patent/IL187416A0/en unknown
2008
- 2008-06-24 CR CR10114A patent/CR10114A/es not_active Application Discontinuation
2009
- 2009-03-26 BG BG10110353A patent/BG66159B1/bg unknown
2010
- 2010-03-10 NO NO2010005C patent/NO2010005I1/no unknown
- 2010-06-10 FI FI20105657A patent/FI121589B/fi not_active IP Right Cessation
2015
- 2015-02-02 HK HK15101088.4A patent/HK1200368A1/en unknown

Also Published As

Publication number	Publication date
HK1036935A1 (en)	2002-01-25
BG106926A (bg)	2003-04-30
IL150513A0 (en)	2003-02-12
CZ20002884A3 (cs)	2001-09-12
ZA200003997B (en)	2000-08-14
GB0001621D0 (en)	2000-03-15
CA2315141C (en)	2009-08-18
CH700184B1 (de)	2010-07-15
ATA13602000A (de)	2004-02-15
CZ298411B6 (cs)	2007-09-26
ES2171123B1 (es)	2003-11-16
IS1940B (is)	2004-07-16
BG106393A (en)	2002-07-31
EE05586B1 (et)	2012-10-15
CA2313783A1 (en)	2000-10-16
DE10038110B4 (de)	2006-06-29
ME00191B (me)	2010-10-10
JP2001206847A (ja)	2001-07-31
SE0002827D0 (sv)	2000-08-04
HUP0003110A2 (hu)	2001-05-28
AP2002002409A0 (en)	2002-03-31
ITTO20000779A1 (it)	2002-02-04
KR100388713B1 (ko)	2003-06-25
SE0002826L (sv)	2001-07-27
IS6254A (is)	2002-01-29
BG110353A (en)	2009-09-30
JP2001206877A (ja)	2001-07-31
IS2805B (is)	2012-09-15
NO20071303L (no)	2001-07-27
YU52902A (sh)	2006-01-16
UA51853C2 (uk)	2002-12-16
ITTO20000779A0 (it)	2000-08-04
CZ290167B6 (cs)	2002-06-12
BE1013414A5 (fr)	2001-12-04
EP2774609A1 (en)	2014-09-10
FI20105657L (fi)	2010-06-10
IL147870A (en)	2003-10-31
KR20000072135A (ko)	2000-12-05
MEP33708A (hr)	2010-10-10
ZA200003998B (en)	2000-08-14
NL1015859A1 (nl)	2001-07-27
PT1223918E (pt)	2003-06-30
US6548513B1 (en)	2003-04-15
EE04990B1 (et)	2008-04-15
EP2133070A1 (en)	2009-12-16
TWI228050B (en)	2005-02-21
ITTO20000780A1 (it)	2000-11-04
AT412063B (de)	2004-09-27
BG65234B1 (bg)	2007-09-28
CA2639407A1 (en)	2001-07-26
AU6580000A (en)	2001-08-07
AU738074B2 (en)	2001-09-06
SI1223918T1 (en)	2003-06-30
HUP0003111A2 (hu)	2002-02-28
NZ531474A (en)	2007-04-27
CH691347A5 (de)	2001-07-13
AU5184100A (en)	2001-08-02
HK1048950A1 (zh)	2003-04-25
EP1251831A1 (en)	2002-10-30
NO20003968D0 (no)	2000-08-04
KR20010077840A (ko)	2001-08-20
HK1040936B (zh)	2010-06-11
AU781269B2 (en)	2005-05-12
AU5184200A (en)	2001-08-02
HU222578B1 (hu)	2003-08-28
CA2315141A1 (en)	2001-07-26
TW553749B (en)	2003-09-21
FI20001749L (fi)	2001-07-27
HUP0003111A3 (en)	2003-03-28
HK1047052A1 (zh)	2003-02-07
RU2002122752A (ru)	2004-03-10
CN1319396A (zh)	2001-10-31
DE10038108A1 (de)	2001-08-02
AU781269C (en)	2006-11-30
EE200200052A (et)	2003-04-15
FI111806B (fi)	2003-09-30
CA2639407C (en)	2011-09-13
BG66168B1 (bg)	2011-10-31
PT102504A (pt)	2001-07-31
PT102503B (pt)	2004-02-27
AU2005202392C1 (en)	2016-06-02
SK11782000A3 (sk)	2001-12-03
UA77156C2 (en)	2006-11-15
ES2155043A1 (es)	2001-04-16
HRP20020097A2 (en)	2002-06-30
NO327675B1 (no)	2009-09-07
IL147870A0 (en)	2002-08-14
NO2010005I1 (no)	2010-05-03
NO20003967L (no)	2001-07-27
AU2000264559A1 (en)	2001-08-07
AR023624A1 (es)	2002-09-04
DK178242B1 (da)	2015-09-28
FR2795324A1 (fr)	2000-12-29
DE60001371D1 (de)	2003-03-13
FI121365B (fi)	2010-10-29
TR200701171T2 (tr)	2007-04-24
NO20003967D0 (no)	2000-08-04
BR0003364A (pt)	2001-09-18
FI20001750A0 (fi)	2000-08-04
AR025055A1 (es)	2002-11-06
NO312434B1 (no)	2002-05-13
PL341853A1 (en)	2001-01-29
HK1036934A1 (en)	2002-01-25
AP1879A (en)	2008-08-14
MEP33808A (hr)	2010-10-10
RU2206324C1 (ru)	2003-06-20
IL150513A (en)	2012-12-31
AT412062B (de)	2004-09-27
IS8620A (is)	2007-03-07
SE0002827L (sv)	2001-07-27
EP2266540A1 (en)	2010-12-29
CL2007001807A1 (es)	2008-01-18
ES2171123A1 (es)	2002-08-16
GB2358582A (en)	2001-08-01
CN1282581A (zh)	2001-02-07
NL1015859C2 (nl)	2001-10-16
EP1223918A1 (en)	2002-07-24
BR0003365A (pt)	2001-09-18
DK200001171A (da)	2001-07-27
EE05221B1 (et)	2009-10-15
SE523471C2 (sv)	2004-04-20
CR10114A (es)	2008-08-21
JP4800467B2 (ja)	2011-10-26
WO2001054669A1 (en)	2001-08-02
KR20030036492A (ko)	2003-05-09
NL1015858C2 (nl)	2001-07-27
JP3267960B2 (ja)	2002-03-25
ES2155043B1 (es)	2001-12-01
ATA13612000A (de)	2004-02-15
JP2007182452A (ja)	2007-07-19
HUP0003110A3 (en)	2003-02-28
SE0002826D0 (sv)	2000-08-04
HRP20080525A2 (en)	2008-12-31
NZ519774A (en)	2004-04-30
DE10038110A1 (de)	2001-08-23
EP2018853A1 (en)	2009-01-28
IL187416A0 (en)	2008-02-09
CR6687A (es)	2005-07-18
SE523481C2 (sv)	2004-04-20
DK1223918T3 (da)	2003-04-28
NO327554B1 (no)	2009-08-10
CA2313783C (en)	2002-03-12
HK1040936A1 (zh)	2002-06-28
FI121589B (fi)	2011-01-31
GB2358583A (en)	2001-08-01
DK200001170A (da)	2001-01-27
SK283872B6 (sk)	2004-03-02
TR200201888T2 (tr)	2002-11-21
EE200900047A (et)	2011-04-15
CZ299105B6 (cs)	2008-04-23
ATE232088T1 (de)	2003-02-15
BE1013413A3 (fr)	2001-12-04
KR100698333B1 (ko)	2007-03-23
GB0019028D0 (en)	2000-09-27
US6316460B1 (en)	2001-11-13
WO2001054668A1 (en)	2001-08-02
YU5202A (sh)	2004-12-31
HRP20020632A2 (en)	2004-12-31
MY123650A (en)	2006-05-31
FI20001749A0 (fi)	2000-08-04
PL196808B1 (pl)	2008-02-29
CZ20002883A3 (cs)	2000-10-11
HRP20020097B1 (hr)	2010-12-31
AP1449A (en)	2005-07-28
AU2005202392B2 (en)	2008-11-20
AP2002002591A0 (en)	2002-09-30
FR2795324B1 (fr)	2002-05-17
JP4800988B2 (ja)	2011-10-26
EP1223918B1 (en)	2003-02-05
DE60001371T2 (de)	2004-01-22
EE200200411A (et)	2003-12-15
PT102503A (pt)	2000-12-29
AR060248A2 (es)	2008-06-04
HU0003110D0 (en)	2000-10-28
FR2804025A1 (fr)	2001-07-27
HRP20020632B1 (en)	2010-12-31
NO20003968L (no)	2001-07-27
GB0019029D0 (en)	2000-09-27
AU2005202392A1 (en)	2005-06-30
RS50201B (sr)	2009-07-15
CN1149997C (zh)	2004-05-19
TR200200270T2 (tr)	2002-06-21
BG66159B1 (bg)	2011-09-30
SK11792000A3 (sk)	2001-12-03
IS6480A (is)	2002-07-23
CN100528161C (zh)	2009-08-19
PL341855A1 (en)	2001-07-30
CN101028268A (zh)	2007-09-05
GB2358583B (en)	2002-02-06
CR6568A (es)	2004-03-05
HK1200368A1 (en)	2015-08-07
FR2804025B1 (fr)	2002-08-23
FI20001750L (fi)	2001-07-27
ME00202B (me)	2010-10-10
HU0003111D0 (en)	2000-10-28
RU2264210C2 (ru)	2005-11-20
GB2358582B (en)	2004-09-29

Publication	Publication Date	Title
MY122707A (en)	2006-04-29	Pharmaceutical compositions
MY129018A (en)	2007-03-30	Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
NZ525419A (en)	2004-12-24	Pharmaceutical formulations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid
UY27271A1 (es)	2003-11-28	Composiciones farmacéuticas
UY30336A1 (es)	2009-01-05	Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma